Prodisc C SK & Vivo vs. Mobi-C for Cervical Disc Disease
(SMART Trial)
Trial Summary
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop your current medications. However, if you are taking medications that interfere with bone or soft tissue healing, like high-dose steroids, immunosuppressants, or chemotherapy agents, you may not be eligible to participate.
What data supports the idea that Prodisc C SK & Vivo vs. Mobi-C for Cervical Disc Disease is an effective treatment?
The available research shows that both Prodisc C and Mobi-C are effective treatments for cervical disc disease. Studies have shown that Mobi-C is effective for treating cervical spondylotic radiculopathy and single-level cervical disc spondylosis, with positive outcomes when compared to traditional surgery methods like anterior cervical disc fusion (ACDF). Similarly, Prodisc-C has shown good long-term results in treating cervical spondylosis, with studies indicating positive clinical outcomes over a 10-year follow-up period. These findings suggest that both treatments can be effective options for managing cervical disc disease.12345
What safety data exists for Prodisc C and Mobi-C in treating cervical disc disease?
The safety data for Prodisc C and Mobi-C in treating cervical disc disease includes several studies. One study analyzed segmental cervical spine vertebral motion after Prodisc-C replacement, indicating it was part of an FDA trial. Another study presented a two-year follow-up on patients with a mobile ProDisc-C implant, suggesting it as an alternative to cervical spine fusion. Additionally, a study evaluated the effectiveness of single segmental cervical disc replacement with ProDisc-C, focusing on changes in the center of rotation. For Mobi-C, a study examined its use in cervical hybrid surgery, observing changes in the center of rotation and anterior bone loss. Another study investigated the clinical effectiveness of Mobi-C for cervical spondylotic radiculopathy. These studies provide insights into the safety and efficacy of these treatments.13678
Is the treatment Prodisc C SK, Prodisc C Vivo a promising treatment for Cervical Disc Disease?
What is the purpose of this trial?
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Research Team
James Kuras
Principal Investigator
Centinel Spine
Eligibility Criteria
This trial is for adults aged 18-69 with cervical disc disease causing neck pain, weakness, or numbness that hasn't improved with treatments like rest or physical therapy. It's not for those who are very overweight, have had certain spine surgeries before, smoke heavily, have osteoporosis, metal allergies, immobile spinal segments, autoimmune diseases affecting the musculoskeletal system or take medication that affects healing.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either the two-level prodisc C SK or prodisc C Vivo device, or the two-level Mobi-C device
Follow-up
Participants are monitored for safety and effectiveness after treatment, including subject questionnaires, X-rays, and neurological assessments
Long-term follow-up
Participants continue to be monitored for up to 5 years to assess long-term safety and effectiveness
Treatment Details
Interventions
- Mobi-C Cervical Disc
- prodisc C SK
- prodisc C Vivo
prodisc C SK is already approved in United States, European Union for the following indications:
- Symptomatic cervical disc disease (SCDD)
- Symptomatic cervical disc disease (SCDD)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Centinel Spine
Lead Sponsor